Full metadata record
DC FieldValueLanguage
dc.creatorCanales-Ruiz, I. (Irene)-
dc.creatorMartelli, M. (Mauricio)-
dc.creatorSehn, L.H. (Laura H.)-
dc.creatorVitolo, U. (Umberto)-
dc.creatorNielsen, T.G. (Tina G.)-
dc.creatorSellam, G. (Gilla)-
dc.creatorBottos, A. (Alessia)-
dc.creatorKlingbiel, D. (Dirk)-
dc.creatorKostakoglu, L. (Lale)-
dc.identifier.citationCanales-Ruiz, I. (Irene); Martelli, M. (Mauricio); Sehn, L.H. (Laura H.); et al. "Baseline total metabolic tumor volume is prognostic for refractoriness to Iimunochemotherapy in DLBCL: results from GOYA". Clinical Lymphoma Myeloma and Leukemia. 22 (8), 2022, e804 - e814es_ES
dc.description.abstractIntroduction A good response to initial therapy is key to maximizing survival in patients with diffuse large B-cell lymphoma (DLBCL), but patients with chemorefractory disease and early progression have poor outcomes. Patients and Methods Data from the GOYA study in patients with DLBCL who received first-line rituximab or obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) were analyzed. Positron emission tomography/computed tomography (PET/CT)-derived characteristics associated with total metabolic tumor volume (TMTV) and clinical risk factors for primary chemorefractory disease and disease progression within 12 months (POD12) were explored. Results Of those patients fulfilling the criteria for analysis, 108/1126 (10%) were primary chemorefractory and 147/1106 (13%) had POD12. Primary chemorefractory and POD12 status were strongly associated with reduced overall survival. After multivariable analysis of clinical and imaging-based risk factors by backward elimination, only very high TMTV (quartile [Q] 1 vs. Q4 odds ratio [OR]: 0.45; P = .006) and serum albumin levels (low vs. normal OR of 1.86; P = .004) were associated with primary chemorefractoriness. After additionally accounting for BCL2/MYC translocation in a subset of patients, TMTV and BCL2/MYC double-hit status remained as significant predictors of primary chemorefractoriness (Q1 vs. Q4 OR: 0.32, P = .01 and double-hit vs. no-hit OR of 4.47, P = .02, respectively). Risk factors including very high TMTV, high sum of the product of the longest diameters (SPD), geographic region (Asia), short time since diagnosis, extranodal involvement and low serum albumin were retained for POD12. Conclusion PET-derived TMTV has prognostic value in identifying patients at risk of early treatment failure.es_ES
dc.description.sponsorshipGOYA was funded by F. Hoffmann-La Roche Ltd. The authors wish to thank the GOYA study team investigators, coordinators, nurses, and patients. GOYA was supported by F. Hoffmann-La Roche Ltd, with scientific support from the Fondazione Italiana Linfomi. Editorial support, under the direction of Lale Kostakoglu, was provided by Louise Profit, PhD, of Ashfield MedComms, an Ashfield Health company, and funded by F. Hoffmann-La Roche Ltd. The authors would like to thank Anastasiia Kinkolykh for her contributions to the data analyses for this manuscript.es_ES
dc.subjectLymphoid malignancieses_ES
dc.subjectPrimary chemorefractory diseasees_ES
dc.subjectPrognostic indicatorses_ES
dc.subjectEarly relapsees_ES
dc.subjectOverall survivales_ES
dc.titleBaseline total metabolic tumor volume is prognostic for refractoriness to Iimunochemotherapy in DLBCL: results from GOYAes_ES
dc.description.noteThis is an open access article under the CC BY-NC-ND licensees_ES
dadun.citation.publicationNameClinical Lymphoma Myeloma and Leukemiaes_ES

Files in This Item:
1.18 MB
Adobe PDF

Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.